Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Drug Profile

Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Alternative Names: Anti-GPC3 CAR-T cells; Anti-GPC3 chimeric antigen receptor T cell therapy - Guangdong Zhaotai InVivo Biomedicine/Hunan Yongren Medical Innovation; CAR-GPC3-T-cells; Glypican-3- chimeric-antigen-receptor-T-cell-therapy - Hunan Yongren Medical Innovation; GPC3-CAR-T cell therapy - Hunan Yongren Medical Innovation; GPC3-T2-CAR-T cell therapy

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Guangdong Zhaotai InVivo Biomedicine; Hunan Yongren Medical Innovation
  • Developer Hunan Yongren Medical Innovation
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Glypican 3 modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Lung cancer

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Lung cancer (Late-stage disease) in China (Parenteral) (NCT03198546)
  • 21 Jun 2017 Hunan Zhaotai Yongren Medical Innovation and Guangdong Zhaotai InVivo Biomedicine in collaboration with Guangzhou Medical University plan a phase I trial for Hepatocellular carcinoma and Lung cancer (Late-stage disease) in China (NCT03198546)
  • 21 Jun 2017 Preclinical trials in Hepatocellular carcinoma in China prior to June 2017 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top